Invida International Trading (Shanghai) Co., Ltd.

This study aimed to determine the efficacy and safety of bilastine 20 mg in the treatment of CIU and to demonstrate that the efficacy of bilastine is comparable to that of levocetirizine 5 mg.

To evaluate the pharmacokinetic parameters of HTZ-312-2 produced by Hisamitsu Pharmaceutical Co., Ltd. and AMD-2 produced by Nitto Denko Corporation after a single, 24-hour administration in healthy Chinese subjects and to verify bioequivalence.

This study was designed to evaluate the pharmacokinetics (PK) of bilastine at different doses in healthy Chinese subjects after single and repeated administration. The primary objective of this study was to determine the PK characteristics of bilastine after oral administration in healthy Chinese subjects. The secondary objectives of this study were to evaluate the safety and tolerability of bilastine after single and repeated administration in healthy Chinese subjects.